Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings ... which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed yesterday at $472.80.

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options become available today, for the December 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up ...

While there are several candidates to make the next stock split announcement, Vertex Pharmaceuticals (NASDAQ:VRTX) may just trump them all when it reports earnings on Nov. 4. Just because a stock ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $540.00. The company’s shares closed ...

We’re looking for the magnitude of that treatment effect. And as you rightfully pointed out, we did not power the study to be able to measure the change from baseline 548 versus placebo, ...

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have appreciated more than 40% since I shifted my coverage to hold/neutral last year, and I am not surprised since the company executed ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...